PF-Atlas › Clinical Trials › NCT01441037

Danazol for Genetic Bone Marrow and Lung Disorders

Danazol · Phase 1

Registry ID

NCT01441037

Phase

Phase 1

Status

Completed

Drug / intervention

Danazol

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Start

2011-07-19

About this trial

Danazol is evaluated in NCT01441037, a Phase 1 idiopathic pulmonary fibrosis study sponsored by National Heart, Lung, and Blood Institute (NHLBI). Current status: Completed.

View NCT01441037 on ClinicalTrials.gov →

Explore related

All Danazol trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT01441037 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.